Metabolomics of Exhaled Breath Condensate by Nuclear Magnetic Resonance Spectroscopy and Mass Spectrometry: A Methodological Approach

2020 ◽  
Vol 27 (14) ◽  
pp. 2381-2399 ◽  
Author(s):  
Mauro Maniscalco ◽  
Adele Cutignano ◽  
Debora Paris ◽  
Dominique J. Melck ◽  
Antonio Molino ◽  
...  

: Respiratory diseases present a very high prevalence in the general population, with an increase in morbidity, mortality and health-care expenses worldwide. They are complex and heterogeneous pathologies that may present different pathological facets in different subjects, often with personal evolution. Therefore, there is a need to identify patients with similar characteristics, prognosis or treatment, defining the so-called phenotype, but also to mark specific differences within each phenotype, defining the endotypes. : Biomarkers are very useful to study respiratory phenotypes and endotypes. Metabolomics, one of the recently introduced “omics”, is becoming a leading technique for biomarker discovery. For the airways, metabolomics appears to be well suited as the respiratory tract offers a natural matrix, the Exhaled Breath Condensate (EBC), in which several biomarkers can be measured. In this review, we will discuss the main methodological issues related to the application of Nuclear Magnetic Resonance (NMR) spectroscopy and Mass Spectrometry (MS) to EBC metabolomics for investigating respiratory diseases.

2018 ◽  
Vol 298 ◽  
pp. 4-12 ◽  
Author(s):  
Mauro Maniscalco ◽  
Debora Paris ◽  
Dominique Melck ◽  
Nunzio Chiariello ◽  
Fiorentino Di Napoli ◽  
...  

2012 ◽  
Vol 39 (2) ◽  
pp. 498-500 ◽  
Author(s):  
A. Motta ◽  
D. Paris ◽  
D. Melck ◽  
G. de Laurentiis ◽  
M. Maniscalco ◽  
...  

2016 ◽  
Vol 9 ◽  
pp. MRI.S40864 ◽  
Author(s):  
Naseer Ahmed ◽  
Tedros Bezabeh ◽  
Omkar B. Ijare ◽  
Renelle Myers ◽  
Reem Alomran ◽  
...  

Objectives Lung cancer is one of the most lethal cancers. Currently, there are no biomarkers for early detection, monitoring treatment response, and detecting recurrent lung cancer. We undertook this study to determine if 1H magnetic resonance spectroscopy (MRS) of sputum and exhaled breath condensate (EBC), as a noninvasive tool, can identify metabolic biomarkers of lung cancer. Materials and Methods Sputum and EBC samples were collected from 20 patients, comprising patients with pathologically confirmed non-small cell lung cancer ( n = 10) and patients with benign respiratory conditions ( n = 10). Both sputum and EBC samples were collected from 18 patients; 2 patients provided EBC samples only. 1H MR spectra were obtained on a Bruker Avance 400 MHz nuclear magnetic resonance (NMR) spectrometer. Sputum samples were further confirmed cytologically to distinguish between true sputum and saliva. Results In the EBC samples, median concentrations of propionate, ethanol, acetate, and acetone were higher in lung cancer patients compared to the patients with benign conditions. Median concentration of methanol was lower in lung cancer patients (0.028 mM) than in patients with benign conditions (0.067 mM; P = 0.028). In the combined sputum and saliva and the cytologically confirmed sputum samples, median concentrations of N-acetyl sugars, glycoprotein, propionate, lysine, acetate, and formate were lower in the lung cancer patients than in patients with benign conditions. Glucose was found to be consistently absent in the combined sputum and saliva samples (88%) as well as in the cytologically confirmed sputum samples (86%) of lung cancer patients. Conclusion Absence of glucose in sputum and lower concentrations of methanol in EBC of lung cancer patients discerned by 1H MRS may serve as metabolic biomarkers of lung cancer for early detection, monitoring treatment response, and detecting recurrence.


Sign in / Sign up

Export Citation Format

Share Document